2,818,429 Shares in Sanofi (NASDAQ:SNY) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in shares of Sanofi (NASDAQ:SNY) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,818,429 shares of the company’s stock, valued at approximately $135,933,000.

A number of other large investors also recently bought and sold shares of the stock. Verdence Capital Advisors LLC raised its stake in Sanofi by 1.3% during the fourth quarter. Verdence Capital Advisors LLC now owns 30,909 shares of the company’s stock worth $1,491,000 after purchasing an additional 386 shares during the period. Aigen Investment Management LP purchased a new position in shares of Sanofi in the 4th quarter valued at $284,000. M&T Bank Corp raised its stake in shares of Sanofi by 571.7% in the 4th quarter. M&T Bank Corp now owns 347,029 shares of the company’s stock valued at $16,738,000 after acquiring an additional 295,361 shares during the period. Assetmark Inc. raised its stake in shares of Sanofi by 64.2% in the 4th quarter. Assetmark Inc. now owns 179,583 shares of the company’s stock valued at $8,661,000 after acquiring an additional 70,208 shares during the period. Finally, Glass Wealth Management Co LLC raised its stake in shares of Sanofi by 1.0% in the 4th quarter. Glass Wealth Management Co LLC now owns 31,145 shares of the company’s stock valued at $1,502,000 after acquiring an additional 300 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on SNY. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Sanofi presently has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Price Performance

SNY opened at $59.25 on Friday. The company has a fifty day simple moving average of $52.44 and a 200 day simple moving average of $52.73. The firm has a market cap of $150.37 billion, a price-to-earnings ratio of 23.80, a PEG ratio of 1.01 and a beta of 0.58. Sanofi has a twelve month low of $45.22 and a twelve month high of $59.72. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.